Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

201510 citationsJournal Articlegold Open Access

Authors

This analysis shows that certolizumab pegol is cost-effective compared with other TNF-inhibitors recommended in Spain for the treatment of RA.

Published in: Cost Effectiveness and Resource Allocation

Volume 13, Issue 1, pp. 11-11

Field-Weighted Citation Impact: 0.54